165 related articles for article (PubMed ID: 9252857)
1. Severe hepatotoxicity on beginning propylthiouracil therapy.
Lock DR; Sthoeger ZM
J Clin Gastroenterol; 1997 Jun; 24(4):267-9. PubMed ID: 9252857
[TBL] [Abstract][Full Text] [Related]
2. Propylthiouracil-induced hepatotoxicity.
Hardee JT; Barnett AL; Thannoun A; Eghtesad B; Wheeler D; Jamal MM
West J Med; 1996 Sep; 165(3):144-7. PubMed ID: 8909171
[No Abstract] [Full Text] [Related]
3. [Acute cholestatic hepatitis induced by propylthiouracil. Case report].
Parolin MB; Lopes RW; Telles JE; Ioshii SO; Hajar N
Arq Gastroenterol; 2000; 37(2):129-32. PubMed ID: 11144016
[TBL] [Abstract][Full Text] [Related]
4. Propylthiouracil-induced severe hepatitis: a case report and review of the literature.
Ichiki Y; Akahoshi M; Yamashita N; Morita C; Maruyama T; Horiuchi T; Hayashida K; Ishibashi H; Niho Y
J Gastroenterol; 1998 Oct; 33(5):747-50. PubMed ID: 9773944
[TBL] [Abstract][Full Text] [Related]
5. A case of autoimmune hepatitis with Graves' disease treated by propylthiouracil.
Sato I; Tsunekawa T; Shinohara Y; Nishio Y; Shimizu Y; Suzuki Y; Yoshioka S
Nagoya J Med Sci; 2011 Aug; 73(3-4):205-9. PubMed ID: 21928702
[TBL] [Abstract][Full Text] [Related]
6. Analysis of Antithyroid Drug-Induced Severe Liver Injury in 18,558 Newly Diagnosed Patients with Graves' Disease in Japan.
Suzuki N; Noh JY; Hiruma M; Kawaguchi A; Morisaki M; Ohye H; Suzuki M; Matsumoto M; Kunii Y; Iwaku K; Yoshihara A; Watanabe N; Sugino K; Ito K
Thyroid; 2019 Oct; 29(10):1390-1398. PubMed ID: 31573408
[No Abstract] [Full Text] [Related]
7. Antineutrophilic cytoplasmic antibody-positive systemic vasculitis associated with propylthiouracil therapy: report of 2 children with Graves' disease.
Poomthavorn P; Mahachoklertwattana P; Tapaneya-Olarn W; Chuansumrit A; Chunharas A
J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1295-301. PubMed ID: 12549809
[TBL] [Abstract][Full Text] [Related]
8. Frequency of appearance of myeloperoxidase-antineutrophil cytoplasmic antibody (MPO-ANCA) in Graves' disease patients treated with propylthiouracil and the relationship between MPO-ANCA and clinical manifestations.
Noh JY; Asari T; Hamada N; Makino F; Ishikawa N; Abe Y; Ito K; Ito K
Clin Endocrinol (Oxf); 2001 May; 54(5):651-4. PubMed ID: 11380496
[TBL] [Abstract][Full Text] [Related]
9. Treatment with propylthiouracil is associated with appearance of antineutrophil cytoplasmic antibodies in some patients with Graves' disease.
Sera N; Ashizawa K; Ando T; Abe Y; Ide A; Usa T; Tominaga T; Ejima E; Yokoyama N; Eguchi K
Thyroid; 2000 Jul; 10(7):595-9. PubMed ID: 10958312
[TBL] [Abstract][Full Text] [Related]
10. Propylthiouracil-induced hepatic damage.
Ozenírler S; Tuncer C; Boztepe U; Akyol G; Alkim H; Cakir N; Kandílć U
Ann Pharmacother; 1996 Sep; 30(9):960-3. PubMed ID: 8876856
[TBL] [Abstract][Full Text] [Related]
11. [Asymptomatic hepatitis induced by propylthiouracil].
De Castro JJ; Nobre EL; Garcia e Costa J; Galvão-Teles A
Acta Med Port; 2001; 14(5-6):523-7. PubMed ID: 11878166
[TBL] [Abstract][Full Text] [Related]
12. Clinical Characteristics and Outcomes of Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibody-Associated Vasculitis in Patients with Graves' Disease: A Median 38-Month Retrospective Cohort Study from a Single Institution in China.
Yang J; Yao LP; Dong MJ; Xu Q; Zhang J; Weng WW; Chen F
Thyroid; 2017 Dec; 27(12):1469-1474. PubMed ID: 29088997
[TBL] [Abstract][Full Text] [Related]
13. Analysis of 90 cases of antithyroid drug-induced severe hepatotoxicity over 13 years in China.
Yang J; Li LF; Xu Q; Zhang J; Weng WW; Zhu YJ; Dong MJ
Thyroid; 2015 Mar; 25(3):278-83. PubMed ID: 25384184
[TBL] [Abstract][Full Text] [Related]
14. Successful Re-administration of Low-dose of Methimazole (MMI) in Graves' Disease Patients Who Experienced Allergic Cutaneous Reactions to MMI at Initial Treatment and Had Received Long-term Propylthiouracil (PTU).
Kubota S
Intern Med; 2016; 55(22):3235-3237. PubMed ID: 27853063
[TBL] [Abstract][Full Text] [Related]
15. Comparison of methimazole and propylthiouracil in the management of children and adolescents with Graves' disease: efficacy and adverse reactions during initial treatment and long-term outcome.
Sato H; Minagawa M; Sasaki N; Sugihara S; Kazukawa I; Minamitani K; Wataki K; Konda S; Inomata H; Sanayama K; Kohno Y
J Pediatr Endocrinol Metab; 2011; 24(5-6):257-63. PubMed ID: 21823520
[TBL] [Abstract][Full Text] [Related]
16. Liver tests in hyperthyroidism: effect of antithyroid therapy.
Gürlek A; Cobankara V; Bayraktar M
J Clin Gastroenterol; 1997 Apr; 24(3):180-3. PubMed ID: 9179740
[TBL] [Abstract][Full Text] [Related]
17. Propylthiouracil-related hemorrhagic diathesis: a case report and review of the literature.
Akarsu E; Buyukhatipoglu H; Aktaran S; Geyik R
Mt Sinai J Med; 2006 Nov; 73(7):1021-3. PubMed ID: 17195890
[TBL] [Abstract][Full Text] [Related]
18. Drug-Induced Liver Injury: A Unique Presentation of Single-Dose Administration of Propylthiouracil.
Weissman S; Rajaratnam NG; Qureshi N; Inayat F; Elias S
J Investig Med High Impact Case Rep; 2020; 8():2324709620951323. PubMed ID: 32830568
[TBL] [Abstract][Full Text] [Related]
19. [Propylthiouracil-induced overt hepatic injury in patients with hyperthyroidism].
Lian XL; Bai Y; Dai WX; Guo ZS; Li W; Lu L
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Apr; 26(2):172-7. PubMed ID: 15171556
[TBL] [Abstract][Full Text] [Related]
20. Propylthiouracil, and methimazole, and carbimazole-related hepatotoxicity.
Akmal A; Kung J
Expert Opin Drug Saf; 2014 Oct; 13(10):1397-406. PubMed ID: 25156887
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
